Display options
Cite
Meester EJ, Krenning BJ, de Blois E, et al. Imaging inflammation in atherosclerotic plaques, targeting SST. J Nucl Cardiol. 2020;28(6):2506-2513doi: 10.1007/s12350-020-02046-y.
Meester, E. J., Krenning, B. J., de Blois, E., de Jong, M., van der Steen, A. F. W., Bernsen, M. R., & van der Heiden, K. (2021). Imaging inflammation in atherosclerotic plaques, targeting SST. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 28(6), 2506-2513. https://doi.org/10.1007/s12350-020-02046-y
Meester, Eric J, et al. "Imaging inflammation in atherosclerotic plaques, targeting SST." Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology vol. 28,6 (2021): 2506-2513. doi: https://doi.org/10.1007/s12350-020-02046-y
Meester EJ, Krenning BJ, de Blois E, de Jong M, van der Steen AFW, Bernsen MR, van der Heiden K. Imaging inflammation in atherosclerotic plaques, targeting SST. J Nucl Cardiol. 2021 Dec;28(6):2506-2513. doi: 10.1007/s12350-020-02046-y. Epub 2020 Feb 05. PMID: 32026330.
Copy Download .nbib Format: NLM
Share it on

J Nucl Cardiol. 2021 Dec;28(6):2506-2513. doi: 10.1007/s12350-020-02046-y. Epub 2020 Feb 05.

Imaging inflammation in atherosclerotic plaques, targeting SST.

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology

Eric J Meester, Boudewijn J Krenning, Erik de Blois, Marion de Jong, Antonius F W van der Steen, Monique R Bernsen, Kim van der Heiden

Affiliations

  1. Department of Biomedical Engineering, Thorax Center, Erasmus Medical Center, PO Box 2040, 3000 CA, Rotterdam, The Netherlands.
  2. Department of Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands.
  3. Department of Cardiology, Thorax Center, Erasmus MC, Rotterdam, The Netherlands.
  4. Department of Biomedical Engineering, Thorax Center, Erasmus Medical Center, PO Box 2040, 3000 CA, Rotterdam, The Netherlands. [email protected].

PMID: 32026330 DOI: 10.1007/s12350-020-02046-y

Abstract

BACKGROUND: Imaging Somatostatin Subtype Receptor 2 (SST

METHODS AND RESULTS: Atherosclerotic ApoE

CONCLUSIONS: The results of this study indicate DOTA-JR11 as a promising ligand for visualization of atherosclerotic plaque inflammation.

© 2020. The Author(s).

Keywords: SPECT; atherosclerosis; inflammation; molecular imaging

References

  1. GBD 2015 Mortality and Causes of Death Collaborators I. Global, regional, and national life expectancy, all-cause mortality, and cause-specifi c mortality for 249 causes of death, 1980–2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016;380(9859):1459-544. https://doi.org/10.1016/S0140-6736(16)31012-1 . - PubMed
  2. Quillard T, Libby P. Molecular imaging of atherosclerosis for improving diagnostic and therapeutic development. Circ Res 2012;111(2):231-44. https://doi.org/10.1161/CIRCRESAHA.112.268144 . - PubMed
  3. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352(16):1685-95. https://doi.org/10.1056/NEJMra043430 . - PubMed
  4. Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: A dynamic balance. Nat Rev Immunol 2013;13(10):709-21. https://doi.org/10.1038/nri3520 . - PubMed
  5. Rudd JHF, Warburton EA, Fryer TD, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation 2002;105(23):2708-11. https://doi.org/10.1161/01.CIR.0000020548.60110.76 . - PubMed
  6. Tawakol A, Migrino R, Hoffmann U, et al. Noninvasive in vivo measurement of vascular inflammation with F-18 fluorodeoxyglucose positron emission tomography. J Nucl Cardiol 2005;12(3):294-301. https://doi.org/10.1016/j.nuclcard.2005.03.002 . - PubMed
  7. Figueroa AL, Subramanian SS, Cury RC, et al. Distribution of inflammation within carotid atherosclerotic plaques with high-risk morphological features a comparison between positron emission tomography activity, plaque morphology, and histopathology. Circ Cardiovasc Imaging 2012;5:69-77. https://doi.org/10.1161/CIRCIMAGING.110.959478 . - PubMed
  8. Rudd JHF, Narula J, Strauss HW, et al. Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography. Ready for prime time? J Am Coll Cardiol 2010;55(23):2527-35. https://doi.org/10.1016/j.jacc.2009.12.061 . - PubMed
  9. Buettner C, Rudd JHF, Fayad ZA. Determinants of FDG uptake in atherosclerosis. JACC Cardiovasc Imaging 2011;4(12):1302-4. https://doi.org/10.1016/j.jcmg.2011.09.011 . - PubMed
  10. Tarkin JM, Joshi FR, Rudd JHF. PET imaging of inflammation in atherosclerosis. Nat Rev Cardiol 2014;11(8):443-57. https://doi.org/10.1038/nrcardio.2014.80 . - PubMed
  11. Elliott DE, Li J, Blum AM, Metwali A, Patel YC, Weinstock JV. SSTR2A is the dominant somatostatin receptor subtype expressed by inflammatory cells, is widely expressed and directly regulates T cell IFN-gamma release. Eur J Immunol 1999;29(8):2454-63. https://doi.org/10.1002/(SICI)1521-4141(199908)29:08%3c2454:AID-IMMU2454%3e3.0.CO;2-H . - PubMed
  12. Dalm VASH, van Hagen PM, van Koetsveld PM, et al. Expression of somatostatin, cortistatin, and somatostatin receptors in human monocytes, macrophages, and dendritic cells. Am J Physiol Endocrinol Metab 2003;285(2):E344-53. https://doi.org/10.1152/ajpendo.00048.2003 . - PubMed
  13. Rominger A, Saam T, Vogl E, et al. In vivo imaging of macrophage activity in the coronary arteries using 68 Ga-DOTATATE PET/CT: Correlation with coronary calcium burden and risk factors. J Nucl Med 2010;51(2):193-7. https://doi.org/10.2967/jnumed.109.070672 . - PubMed
  14. Li X, Bauer W, Kreissl MC, et al. Specific somatostatin receptor II expression in arterial plaque: 68 Ga-DOTATATE autoradiographic, immunohistochemical and flow cytometric studies in apoE-deficient mice. Atherosclerosis 2013;230(1):33-9. https://doi.org/10.1016/j.atherosclerosis.2013.06.018 . - PubMed
  15. Rinne P, Hellberg S, Kiugel M, et al. Comparison of somatostatin receptor 2-targeting PET tracers in the detection of mouse atherosclerotic plaques. Mol Imaging Biol 2015;18(1):99-108. https://doi.org/10.1007/s11307-015-0873-1 . - PubMed
  16. Mojtahedi A, Alavi A, Thamake S, et al. Assessment of vulnerable atherosclerotic and fibrotic plaques in coronary arteries using 68 Ga-DOTATATE PET/CT. Am J Nucl Med Mol Imaging 2015;5(1):65-71. - PubMed
  17. Malmberg C, Ripa RS, Johnbeck CB, et al. 64Cu-DOTATATE for non-invasive assessment of atherosclerosis in large arteries and its correlation with risk factors: Head-to-head comparison with 68 Ga-DOTATOC in 60 patients. J Nucl Med 2015;2015:1-33. https://doi.org/10.2967/jnumed.115.161216 . - PubMed
  18. Pedersen SF, Sandholt BV, Keller SH, et al. - PubMed
  19. Wan MYS, Endozo R, Michopoulou S, et al. PET/CT imaging of unstable carotid plaque with - PubMed
  20. Tarkin JM, Joshi FR, Evans NR, et al. Detection of atherosclerotic inflammation by 68 Ga-DOTATATE PET compared to [18F]FDG PET imaging. J Am Coll Cardiol 2017;69(14):1774-91. https://doi.org/10.1016/j.jacc.2017.01.060 . - PubMed
  21. Fani M, Nicolas GP, Wild D. Somatostatin receptor antagonists for imaging and therapy. J Nucl Med 2017;58(Supplement 2):61S-6S. https://doi.org/10.2967/jnumed.116.186783 . - PubMed
  22. Wild D, Fani M, Fischer R, et al. Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study. J Nucl Med 2014;55(8):1248-53. https://doi.org/10.2967/jnumed.114.138834 . - PubMed
  23. Dalm SU, Nonnekens J, Doeswijk GN, et al. Comparison of the therapeutic response to treatment with a 177Lu-labeled somatostatin receptor agonist and antagonist in preclinical models. J Nucl Med 2016;57(2):260-6. https://doi.org/10.2967/jnumed.115.167007 . - PubMed
  24. Krebs S, Pandit-Taskar N, Reidy D, et al. Biodistribution and radiation dose estimates for 68 Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2019;46(3):677-85. https://doi.org/10.1007/s00259-018-4193-y . - PubMed
  25. De Blois E, Schroeder RJ, de Ridder CMA, van Weerden W, Breeman WAP, de Jong M. Improving radiopeptide pharmacokinetics by adjusting experimental conditions for bombesin receptor-mediated imaging of prostate cancer. Q J Nucl Med Mol Imaging 2012;57:1-9. - PubMed
  26. de Blois E, Chan HS, de Zanger R, Konijnenberg M, Breeman WAP. Application of single-vial ready-for-use formulation of 111In- or 177Lu-labelled somatostatin analogs. Appl Radiat Isot 2014;85:28-33. https://doi.org/10.1016/j.apradiso.2013.10.023 . - PubMed
  27. Ogawa K, Harata Y, Ichihara T, Kubo A, Hashimoto S. A practical method for position-dependent compton-scatter correction in single photon emission CT. IEEE Trans Med Imaging 1991;10(3):408-12. https://doi.org/10.1109/42.97591 . - PubMed
  28. Vaissier PEB, Beekman FJ, Goorden MC. Similarity-regulation of OS-EM for accelerated SPECT reconstruction. Phys Med Biol 2016;61(11):4300-15. https://doi.org/10.1088/0031-9155/61/11/4300 . - PubMed
  29. Hofland LJ, Lamberts SWJ, Van Hagen PM, et al. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs. J Nucl Med 2003;44(8):1315-21. - PubMed
  30. Ferone D, Pivonello R, Kwekkeboom DJ, et al. Immunohistochemical localization and quantitative expression of somatostatin receptors in normal human spleen and thymus: Implications for the in vivo visualization during somatostatin receptor scintigraphy. J Endocrinol Invest 2012;35(5):528-34. https://doi.org/10.3275/7871 . - PubMed
  31. Ginj M, Zhang H, Waser B, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci USA 2006;103(44):16436-41. https://doi.org/10.1073/pnas.0607761103 . - PubMed
  32. Fani M, Braun F, Waser B, et al. Unexpected sensitivity of sst 2 antagonists to N-terminal radiometal modifications. J Nucl Med 2012;202:1481-90. https://doi.org/10.2967/jnumed.112.102764 . - PubMed

Publication Types